Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home News

FDA launches new AI-powered system to track drug and vaccine side effects nationwide

admin by admin
March 11, 2026
in News
0
FDA launches new AI-powered system to track drug and vaccine side effects nationwide
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

The Food and Drug Administration (FDA) rolled out a new platform, backed by artificial intelligence, that will streamline publicly accessible reporting of negative or unexpected health effects linked to medicines, vaccines, cosmetics, animal food and other consumer products.

The FDA Adverse Event Monitoring System (AEMS) began operation Tuesday and will consolidate outdated systems used to process millions of adverse event reports and produce results in real time for consumers to access online. 

‘The FDA’s fragmented adverse event systems have wasted taxpayer dollars and created large blind spots in our post-market surveillance,’ FDA Commissioner Dr. Marty Makary told Fox News Digital in a statement. ‘We’re addressing this critical issue by conducting a major modernization initiative on an accelerated timeline.’ 

‘Moving forward, the FDA will have a single, intuitive adverse event platform that will better equip us and any interested researcher to access key data and insights about the safety of products on the market,’ Makary added.

Adverse event reports are critical to determining the safety and effectiveness of certain drugs and products after they are approved for clinical trials and reach the wider consumer market, though the agency says the reports have been undermined due to current inefficient infrastructure.

The general concept of AEMS is that consumers will be able to access the new website and search for FDA-approved cosmetics, drugs, vaccines, or foods that have adverse effect reports as they are reported by healthcare professionals, consumers, manufacturers, and user facilities for medical devices. 

The agency estimates that roughly 6 to 7 million adverse event reports per year are evaluated through a seven database system. The FDA says that the collective cost of utilizing the database is an estimated $37 million bill to taxpayers. AEMS is expected to save the FDA approximately $120 million over the next five years, according to the agency.

The new website will be more accessible than the current quarterly report issued by the agency, and senior sources at the FDA told Fox News Digital they saw a 3,000% increase in users in a pilot program that launched last September.

‘Consolidating the FDA’s adverse event systems and converting to real-time publication was challenging, but made possible by a highly aggressive schedule,’ the FDA’s Chief AI Officer Jeremy Walsh told Fox News Digital in a statement. ‘The team executed with perfection and delivered the biggest technical transformation in agency history. This is the new FDA.’

The legacy systems that are currently in place include the FDA Adverse Event Reporting System (FAERS),  Vaccine Adverse Event Reporting System (VAERS), and Adverse Event Reporting System (AERS), which will be replaced with the new system effective immediately. 

In May, the AEMS will also replace the Manufacturer and User Facility Device Experience (MAUDE), Human Foods Complaint System (HFCS), and Center for Tobacco Products Adverse Event Reporting System (CTPAE).

Each one of these systems will be integrated into the new AEMS, with artificial intelligence assisting for manual data entries and coding adverse events. 

Sources at the FDA told Fox News Digital that the next phase of the rollout will be implementing a front-end system that makes it easy for reports to be submitted. The agency estimates that 80% of reports are never entered due to the complexity of filing a report — potentially resulting in some untold side effects never being made public. 

Preston Mizell is a writer with Fox News. Story tips can be sent to Preston.Mizell@fox.com and on X @MizellPreston

This post appeared first on FOX NEWS

Previous Post

Cornyn reverses on filibuster stance to push Trump’s SAVE Act in Senate

Next Post

171 million travelers face airport delays as Democrats’ DHS shutdown hits TSA staffing, Scalise warns

Next Post
171 million travelers face airport delays as Democrats’ DHS shutdown hits TSA staffing, Scalise warns

171 million travelers face airport delays as Democrats’ DHS shutdown hits TSA staffing, Scalise warns

  • Trending
  • Comments
  • Latest
Starbucks to pay about $35M to NYC workers to settle claims it violated labor law

Starbucks to pay about $35M to NYC workers to settle claims it violated labor law

December 3, 2025
Saks files for bankruptcy as luxury market struggles

Saks files for bankruptcy as luxury market struggles

January 15, 2026
Coinbase stock flips crucial support level as losses jump: can it hit $100?

Coinbase stock flips crucial support level as losses jump: can it hit $100?

February 13, 2026
Bondi confirms DOJ has received criminal referral alleging Brennan perjury over Steele dossier

Bondi confirms DOJ has received criminal referral alleging Brennan perjury over Steele dossier

February 11, 2026
US stocks close in red as S&P 500 dips on oil rally and geopolitics

US stocks close in red as S&P 500 dips on oil rally and geopolitics

0
Apple’s AI chief abruptly steps down

Apple’s AI chief abruptly steps down

0
Trump Media to merge with nuclear fusion company

Trump Media to merge with nuclear fusion company

0
Warner Bros. Discovery rejects Paramount’s amended takeover offer

Warner Bros. Discovery rejects Paramount’s amended takeover offer

0
US stocks close in red as S&P 500 dips on oil rally and geopolitics

US stocks close in red as S&P 500 dips on oil rally and geopolitics

March 15, 2026
S&P 500 and VOO stock: Top catalysts to watch this week

S&P 500 and VOO stock: Top catalysts to watch this week

March 15, 2026
In the Money: Definition, Call & Put Options, and Example

In the Money: Definition, Call & Put Options, and Example

March 15, 2026
US stocks close in red as S&P 500 dips on oil rally and geopolitics

US stocks close in red as S&P 500 dips on oil rally and geopolitics

March 14, 2026

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    US stocks close in red as S&P 500 dips on oil rally and geopolitics

    US stocks close in red as S&P 500 dips on oil rally and geopolitics

    March 15, 2026
    S&P 500 and VOO stock: Top catalysts to watch this week

    S&P 500 and VOO stock: Top catalysts to watch this week

    March 15, 2026
    In the Money: Definition, Call & Put Options, and Example

    In the Money: Definition, Call & Put Options, and Example

    March 15, 2026
    US stocks close in red as S&P 500 dips on oil rally and geopolitics

    US stocks close in red as S&P 500 dips on oil rally and geopolitics

    March 14, 2026
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved